TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01671774
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg on d 1 of cycle 1 and cycle 3
Study: NCT03043989
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 doses of clarithromycin with either Docetaxel or Cabazitaxel
Study: NCT04029038
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00268398
Drug: oxaliplatin, folinic acid, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
Study: NCT00268398
Drug: oxaliplatin, irinotecan, folinic acid, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)
Study: NCT03313960
Drug: Afrezza plus One Drop | Premium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).
Study: NCT01654250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03931785
Drug: MD-7246
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03931785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral tablet
Study: NCT02144246
Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00680836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally two times per day for 14 days
Study: NCT01531803
Drug: Kedbumin 25%
Normalized name: Kedbumin 25% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
Study: NCT03881878
Drug: TAHP plus AC and AHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks
Study: NCT01034657
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
Study: NCT03675555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
Study: NCT03309475
Drug: Psychotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual delivered by patient's practitioner
Study: NCT01450267
Drug: Inhaled Reduced Glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg, twice daily, 12 months
Study: NCT01450267
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,13 ml/kg body weight, twice daily, 12 months
Study: NCT04431778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Study: NCT01436890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet in triple dummy format, Once daily for 12 weeks
Study: NCT04483219
Drug: TKI ± anti-PD-1 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.
Study: NCT01104870
Drug: UT-15C
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03760640
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01008046
Drug: combined N-acetyl cysteine -CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Study: NCT04579419
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 NaCl
Study: NCT00122863
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01391299
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
Study: NCT02344355
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
Study: NCT05639803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml/vial
Study: NCT00720811
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
Study: NCT00720811
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
Study: NCT01766843
Drug: Seretide Diskus and charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT01766843
Drug: SF Easyhaler and charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT03997838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0 mg of VVZ-149
Study: NCT01036139
Drug: BF2.649 (pitolisant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study: NCT03115515
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
Study: NCT01872754
Drug: 1: Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
Study: NCT04269187
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline oral 200 mg daily for 12 days
Study: NCT03378934
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for 12±1 weeks.
Study: NCT01923974
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01923974
Drug: Melatonin 100 mg
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01923974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00290628
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03933631
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate ophthalmic suspension 1%
Study: NCT01647880
Drug: Verum arm receiving Gilenya®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01647880
Drug: Active Comparator receiving Extavia®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01642667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02572687
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02241772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02965456
Drug: IDP 121 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT02965456
Drug: IDP-121 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT04043104
Drug: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
Study: NCT04043104
Drug: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
Study: NCT03325803
Drug: MAL application
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study: NCT03948620
Drug: Macrolides
Normalized name: Macrolides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
Study: NCT03948620
Drug: Penicillins
Normalized name: (INACTIVE) PENICILLINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
Study: NCT04044287
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
Study: NCT03702374
Drug: Combined antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
Study: NCT03748212
Drug: D935 Cap. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fed condition
Study: NCT03748212
Drug: CKD-385 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fed condition
Study: NCT03262038
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
Study: NCT01217411
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03944876
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Study: NCT02635672
Drug: VIP152 (BAY 1251152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
Study: NCT02635672
Drug: VIP152 (BAY 1251152) 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
Study: NCT02635672
Drug: VIP152 (BAY 1251152) 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
Study: NCT02362412
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet containing 50 mg or 150 mg of quetiapine taken orally.
Study: NCT02738697
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
Study: NCT03997734
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and repeated dosing
Study: NCT00265642
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet per day during 2 years
Study: NCT00641212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01523431
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The LV dosage will remain the standard.
Study: NCT01505426
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01505426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02623439
Drug: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Study: NCT00816673
Drug: placebo Circadin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tabs of Prolonged release melatonin
Study: NCT04082442
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT00863460
Drug: MTX based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
Study: NCT02834442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04359680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for six weeks
Study: NCT00520572
Drug: AZD9056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00520572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00409227
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once a day for 3 months or stone free
Study: NCT00660959
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02504775
Drug: Mejoral® 500 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet of paracetamol
Study: NCT02504775
Drug: Tylenol® Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet of paracetamol
Study: NCT03142204
Drug: [18F]F-AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV injection of \[18F\]F-AraG for each imaging day.
Study: NCT01230814
Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
Study: NCT01230814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
Study: NCT00919490
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, see arms for interventional description
Study: NCT00919490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, see arms for interventional description.
Study: NCT01748552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT01748552
Drug: LY2922083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT03387579
Drug: Smoflipid 20% Lipid Emulsion for Injection
Normalized name: Smoflipid 20% Lipid Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
Study: NCT03387579
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
Study: NCT03387579
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
Study: NCT02224079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropyl-beta-cyclodextrin (HPβCD)
Study: NCT00432991
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL, IM (in the muscle), one time
Study: NCT02598999
Drug: bLF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for inhalation administered through nebulization
Study: NCT02598999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
Study: NCT04294160
Drug: LTT462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT01830101
Drug: TMZ plus concurrent re-irradiation
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03240055
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
Study: NCT04432298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile liquid for injection
Study: NCT01818648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
Study: NCT01038895
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet; 300 mg; od; 3 months